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Abstract
Background: Myelolipoma is a rare benign tumor composed of mature adipose tissue and normal hematopoietic
tissue. Although surgical resection has been recommended due to the potential of progressive enlargement, the
natural history of mediastinal myelolipoma has not yet been described. Herein we report a surgically resected
mediastinal myelolipoma showing gradual enlargement over a period of 9 years.
Case presentation: A 70-year-old woman presented with a posterior mediastinal mass shadow detected by
computed tomography (CT) examination. She had a medical history of sigmoidectomy for colon cancer 13 years
previously. A CT scan showed a smooth, well-demarcated 2.8 × 2.1-cm paravertebral mass shadow, composed of a
fat density area and a soft tissue density area, which showed gradual enlargement from a 1.6 × 1.0-cm nodule
9 years previously. This was not accompanied by chronic anemia or hematologic disease including thalassemia, and
no abnormal accumulation was observed on bone marrow scintigraphy or fluoro-2-deoxyglucose positron emission
tomography. With a clinical diagnosis of mediastinal myelolipoma, surgical resection was performed, and
pathological examination confirmed the diagnosis.
Conclusions: We experienced a rare case with mediastinal myelolipoma showing gradual enlargement, with a
tumor doubling time of 1,212 days.
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Background
Myelolipoma is a rare benign tumor composed of ma-
ture adipose tissue and normal hematopoietic tissue.
Myelolipoma was first described by Gierke in 1905 and
named by Oberling in 1929 [1]. Most myelolipomas are
asymptomatic and discovered at autopsy, and their esti-
mated incidence is 0.08 to 0.2 % [2]. The most common
site of involvement is the adrenal gland, although extra-
adrenal lesions have also been described, particularly in
the presacral or retroperitoneal space [2]. Intrathoracic
myelolipomas have rarely been reported [3–5]: 28 cases
of mediastinal myelolipomas have been reviewed in the
literature [5]. Although surgical resection has been rec-
ommended for mediastinal myelolipoma due to the
potential of progressive enlargement, the natural history
of mediastinal myelolipoma has not yet been described.
Herein we report a surgically resected mediastinal mye-
lolipoma showing gradual enlargement over a 9-year
period.
Case presentation
A 70-year-old woman presented with a posterior medi-
astinal mass shadow detected by computed tomography
(CT) examination triggered by a slightly elevated CEA
level of 7.0 ng/mL. She had a medical history of sigmoi-
dectomy for colon cancer 13 years previously and had a
smoking history of 12 pack-years. A CT scan showed a
smooth, well-demarcated 2.8 × 2.1-cm paravertebral
mass shadow, composed of a fat density area and a soft
tissue density area, which showed gradual enlargement
from a 1.6 × 1.0-cm nodule 9 years previously (Fig. 1).
Magnetic resonance imaging showed low signal intensity
on T1- and T2-weighted images, with a small area of
high T1 intensity that was depressed on fat depression
imaging. Due to the existence of a fat component, medi-
astinal myelolipoma, extramedullary hematopoiesis, and
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well-differentiated liposarcoma were suspected. The mass
was not accompanied by chronic anemia or hematologic
disease including thalassemia, and no abnormal accumula-
tion was observed on bone marrow scintigraphy or fluoro-
2-deoxyglucose positron emission tomography. Based on a
clinical diagnosis of mediastinal myelolipoma, surgical
resection was performed with video-assisted thoracoscopic
surgery. The lesion was a well-encapsulated, soft and purple
mass in the posterior mediastinum (Fig. 2a, b). Frozen
section examination was consistent with myelolipoma, and
a b
Fig. 1 CT scan showing a 1.6 × 1.0-cm nodule 9 years previously (a), with gradual enlargement to a smooth, well-demarcated 2.8 × 2.1-cm
paravertebral mass shadow, composed of a fat density area and a soft tissue density area (b)
a b
c
Fig. 2 Video-assisted thoracoscopy showing a purple mass in the posterior mediastinum (a). Resected specimen showing a well-encapsulated
soft tumor (b). Microscopic examination showing adipocytes admixed with normal hematopoietic elements, including megakaryocytes and cells
of granulopoietic and erythropoietic lineages (H&E, x400, c)
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pathological examination confirmed the diagnosis (Fig. 2c).
The postoperative course was uneventful, and the patient is
well without recurrence 8 months after surgery.
Discussion
Mediastinal myelolipomas are typically asymptomatic
[3]. They tend to be incidentally detected during radio-
logical investigation of unrelated symptoms. The tumor
size ranges from 1.5 to 25 cm, suggesting the potential
for continuous growth [5]. The surgical indication for
mediastinal myelolipoma remains a matter of controversy.
While myelolipoma is benign and generally asymptomatic,
most myelolipomas are surgically removed due to the po-
tential for progressive enlargement and uncertainty with
respect to the preoperative diagnosis [4]. For early-stage
disease, surgical resection with minimally invasive video-
assisted thoracoscopic surgery is recommended, based on
the assumption that delayed surgery might be associated
with more surgical risks and invasiveness [4]. Although
the potential for progressive growth has been repeatedly
mentioned and surgical resection is recommended, the nat-
ural history of mediastinal myelolipoma has not yet been
demonstrated, and the growth rate remains uncertain. With
respect to intrathoracic myelolipoma, a case of pulmonary
myelolipoma, showing slight enlargement from 1.8 cm to
2.5 cm over 13 years, has been reported [6]. The present
case showed gradual enlargement from 1.6 × 1.0 cm to
2.8 × 2.1 cm over 9 years, with a tumor doubling time of
1,212 days. Although no conclusions can be drawn from
these limited observations, these two cases of intrathoracic
myelolipoma (mediastinal and pulmonary) demonstrated
progressive enlargement as expected.
In contrast, not all cases of adrenal myelolipoma dem-
onstrate continuous growth. The natural history of 16 ad-
renal myelolipomas has been reported to be an average of
3.2 years (range, 0.3 to 10.8 years) [7]. Among these, 13
tumors were serially imaged, with tumor size increasing in
6 tumors, decreasing in 2 tumors, and remaining un-
changed in 5 tumors. Compared to the initial mean tumor
size of 5.1 cm (range, 2.2 to 12 cm), the follow-up mean
tumor size was 5.6 cm (range, 2.5 to 17 cm). These data
may suggest that at least half of adrenal myelolipomas can
be treated conservatively [8].
The other factor influencing indication for surgery is
the risk of spontaneous rupture and bleeding, which has
been reported to be related to tumor size [2, 8]. Among
the 86 myelolipomas encountered at the Armed Forces
Institute of Pathology, including 14 extra-adrenal myelo-
lipomas, nine patients presented with acute hemorrhage
[2]. Based on the observation that the smallest lesion
that bled had a diameter of 8.5 cm while all of the others
had a diameter > 10 cm (mean, 14.2 cm), elective surgery
for large myelolipomas > 10 cm was recommended [2].
Another recommendation suggested that symptomatic
tumors or myelolipomas > 7 cm should be surgically
removed due to an increased risk of spontaneous rup-
ture with retroperitoneal hemorrhage [8]. In contrast,
small asymptomatic tumors < 4 cm can be monitored
expectantly since they pose little risk of spontaneous
rupture or bleeding [8].
Histologically, myelolipoma is a benign tumor com-
posed of mature adipose tissue and hematopoietic cells,
including myeloid, erythroid, and megakaryocytic ele-
ments, and occasionally lymphocytes [6]. Myelolipoma is
distinct from extramedullary hematopoietic tissue, which
occurs in association with hematologic disease and
splenomegaly, does not contain fat, and is usually multi-
focal [2]. Extramedullary hematopoietic tumors show
different characteristics with abnormal hematopoietic
components, and erythroid hyperplasia is common [4].
CT scanning demonstrates an encapsulated mass, the
density of which depends on the relative proportion of fat
(low density) and hematopoietic tissue (high density); this
may be enhanced following administration of intravenous
contrast agents. Small amounts of calcification may also
be observed [2, 6, 9]. CT-guided needle biopsy was re-
ported to be useful for avoiding surgery in asymptomatic
patients; however, the potential risks of dissemination in
the case of malignant neoplasm and hemorrhage in the
case of extramedullary hematopoiesis were noted [9].
Conclusion
A surgical indication for mediastinal myelolipoma has been
proposed due to the potential for continuous enlargement,
uncertain preoperative diagnosis, and risk of spontaneous
rupture and bleeding. While the natural history of medias-
tinal myelolipoma has not yet been described, the present
case demonstrates gradual enlargement over a period of
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